Prograf Ads Mislead On CV, Nephrotoxicity Risk – DDMAC
This article was originally published in The Pink Sheet Daily
Executive Summary
Warning letter to Astellas is not the first time FDA has cited Prograf ads for downplaying risks.
You may also be interested in...
Astellas' Once-Daily Prograf Receives Mixed Decisions For Three Prophylaxis Claims
Astellas Pharma's once-daily immunosuppressant Prograf MR, a modified-release formulation of tacrolimus, is "approvable" in the U.S. for prophylaxis of organ rejection in kidney and liver transplantation but "not approvable" for heart transplant patients, the company said Jan. 23
Astellas’ Once-Daily Prograf Receives Mixed Decisions For Three Prophylaxis Claims
Company also inks monoclonal antibody deal with Kirin Brewery.
Astellas’ Once-Daily Prograf Receives Mixed Decisions For Three Prophylaxis Claims
Company also inks monoclonal antibody deal with Kirin Brewery.